A p53 GROWTH ARREST PROTECTS FIBROBLASTS FROM ANTICANCER AGENTS

E. Siobhan McCormack, Arthur M. Bruskin, Gary V. Borzillo

OSI Pharmaceuticals Inc., 106 Charles Lindbergh Blvd., Uniondale, NY 11553-3649

Received 10/27/97 Accepted October 31, 1997

7. REFERENCES

1. Sonis S. T, L. Lindquist, A. Van Vugt, A. A. Stewart, K. Stam, G.-Y. Qu, K. K. Iwata & J. D. Haley: Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta-3. Cancer Res 54, 1135-1138 (1994)

2. Lemoli R. M, A. Strife, B. D. Clarkson, J. D. Haley & S. C. Gulati: TGF-beta3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro. Exp Hematol 20, 1252-1256 (1992).

3. Grzegorzewski K, F. W. Ruscetti, N. Usui, G. Damia, D. L. Longo, J. Carlino, J. R. Keller & R. H. Wiltrout: Recombinant transforming growth factor beta1 and beta2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J Exp Med 180, 1047-1057 (1994)

4. Pierce D. E. & R. J. Coffey: Therapeutic manipulation of cytokines: transforming growth factor beta-1 protects mice treated with lethal doses of cytarabine. Am Surg 60, 18-25 (1994)

5. McCormack E. S, G. V. Borzillo, C. Ambrosino, G. Mak, L. Hamablet, G.-Y. Qu & J. D. Haley: Transforming growth factor beta-3 protection of epithelial cells from cycle selective chemotherapy in vitro. Biochem Pharmacol 53, 1149-1159 (1997)

6. Potten C. S: Interleukin-11 protects the clonogenic stem cells in murine small-intestinal crypts from impairment of their reproductive capacity by radiation. Int J Cancer 62, 356-361 (1995)

7. Hinds P, C. A. Finlay, R. S. Quartin, S. J. Baker, E. R. Fearon, B. Vogelstein & A. J. Levine: Mutant p53 DNA clones from human carcinomas cooperate with ras in transforming primary rat calls: a comparison of the "hot-spot" mutant phenotypes. Cell Growth Differ 1, 571-580 (1990)

8. Martinez J, I. Georgoff, J. Martinez & A. J. Levine: Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 5, 151-159 (1991)

9. Olson D. C, V. Marechal, J. Momand, J. Chen, C. Romocki & A. J. Levine: Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 complexes. Oncogene 8, 2353-2360 (1993)

10. Kern S. E, K. W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives & B. Vogelstein: Identification of p53 as a sequence-specific DNA-binding protein. Science 252, 1708-1711 (1991)

11. Zhang W, X.-Y. Guo, G.-Y. Hu, J. W. Shay & A. B. Deisseroth: A temperature-sensitive mutant of human p53. EMBO J 13, 1535-2544 (1994)

12. Matozaki T, C. Sakamoto, K. Matsuda, T. Suzuki, Y. Konda, O. Nakano, K. Wada, T. Uchida, H. Nishisaki, M. Nagao & M. Kasuga: Missense mutations and a deletion of the p53 gene in human gastric cancer. Biochem Biophys Res Commun 182, 215-223 (1992)

13. Goldfarb M, K. Shimizu, M. Perucho & M. Wigler: Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature 296, 404-409 (1982)

14. El-Deiry W. S, T. Tokino, V. E. Velescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler & B. Vogelstein: WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993)

15. Macleod K. F, N. Sherry, G. Hannon, D. Beach, T. Tokino, K. Kinzler, B. Vogelstein & T. Jacks: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9, 935-944 (1995)

16. M. R. Cooper & M. R. Cooper: Principles of medical oncology. In: American Cancer Society Textbook of Clinical Oncology. Eds: Holleb A, Fink D, Murphy G, American Cancer Society, Atlanta (1991)

17. Sherr C. J. & J. M. Roberts: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9, 1149-1163 (1995)

18. Hawkins D. S, G. W. Demers & D. A. Galloway: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56, 892-898 (1996)

19. Fan S, M. L. Smith, D. J. Rivet II, D. Duba, Q. Zhan, K. W. Kohn, A. J. Fornance Jr & P. M. O'Connor: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55, 1649-1654 (1995)

20. Clarke A. R, C. A. Purdie, D. J. Harrison, R. G. Morris, C. C. Bird, M. L. Hooper & A. H. Wyllie: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 847-849 (1993)

21. Wu X & A. J. Levine: p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 91, 3602-3606 (1994)

22. Morgenbesser S. D, B. O. Williams, T. Jacks & R. A. DePinho: p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371, 72-74 (1994)

23. Cross S. M, C. A. Sanchez, C. Morgan, M. K. Schimke, S. Ramel, R. L. Idzerda, W. H. Raskind & B. Reid: A p53-dependent mouse spindle checkpoint. Science 267, 1353-1356 (1995)

24. Hupp T. R & D. L. Lane: Allosteric activation of latent p53 tetramers: Curr Biol 4, 865-875 (1994)

25. Hupp T. R, A. Sparks & D. L. Lane: Small peptides activate the latent sequence-specific binding function of p53. Cell 83, 237-245 (1995)

26. Selivanova G, V. Iotsova, I. Okan, M. Fritsche, M. Strom, B. Groner, R. C. Grafstrom & K. G. Wiman: Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 c-terminal domain. Nat Med 3, 632-638 (1997)